ArticlePharmacoEconomics - open2023

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China.

Shanlian Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.